Jpn. J. Pharmacol. 72 (2), 127-135 (1996)

HMN-709, a Chlorobenzenesulfonamide Derivative, Is a New Membrane-Permeable Calmodulin Antagonist

Hisayuki Yokokura, Yohei Okada, Osamu Terada and Hiroyoshi Hidaka (*)

The Department of Pharmacology, Nagoya University School of Medicine, 65 Tsurumai, Showa-ku, Nagoya 466, Japan (*) To whom correspondence should be addressed.

Abstract: Our objective is to describe the basic chemical and biological properties of the new calmodulin antagonist HMN-709 (2-[N-(2-aminoethyl)-N-(4-chlorobenzenesulfonyl)]amino-N-(4-fluorocinnamyl)-N-methylbenzylamine). This newly synthesized compound was found to inhibit the Ca2+/calmodulin-dependent activation of calmodulin kinase I, smooth muscle myosin light chain kinase and Ca2+-phosphodiesterase with IC50 values of 1.57+/-0.21, 2.29+/-0.09 and 0.30+/-0.08 microM (mean+/-S.E.), respectively. This compound showed little or no effect on the Ca2+/calmodulin-independent activation of protein kinase A, protein kinase C and basal phosphodiesterase. In addition, HMN-709 inhibited calmodulin kinase I competitively with respect to calmodulin (Ki = 0.88 microM) and non-competitively with respect to ATP. Affinity chromatography, with HMN-709-coupled Sepharose HP, showed that the compound bound to calmodulin in a Ca2+-dependent manner and did not bind to calmodulin kinase I. These results suggest that HMN-709 antagonizes calmodulin by binding to Ca2+/calmodulin. HMN-709 inhibited collagen-induced platelet aggregation with an IC50 value of 11.80+/-0.86 microM (mean+/-S.E.) without inhibiting phorbol 12,13-dibutyrate-induced aggregation at doses up to 12 microM. HMN-709 appears to be a new, membrane-permeable calmodulin antagonist that may be used for studying the involvement of calmodulin in cellular processes.

Keywords: Calmodulin, Calmodulin antagonist, IC50, Affinity chromatography, Platelet function

Copyright© The Japanese Pharmacological Society 1996

[Back to TOC]